Rivoglitazone: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Rivoglitazone": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))
 
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)
 
(One intermediate revision by the same user not shown)
Line 28: Line 28:
{{CMG}}
{{CMG}}


{{EH}}
 


'''Rivoglitazone''' ([[International Nonproprietary Name|INN]]) is a [[thiazolidinedione]] undergoing research for use in the treatment of [[type 2 diabetes]].<ref name="pmid17458185">{{cite journal |author=Schimke K, Davis TM |title=Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes |journal=Curr Opin Investig Drugs |volume=8 |issue=4 |pages=338–44 |year=2007 |pmid=17458185 |doi=}}</ref>
'''Rivoglitazone''' ([[International Nonproprietary Name|INN]]) is a [[thiazolidinedione]] undergoing research for use in the treatment of [[type 2 diabetes]].<ref name="pmid17458185">{{cite journal |author=Schimke K, Davis TM |title=Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes |journal=Curr Opin Investig Drugs |volume=8 |issue=4 |pages=338–44 |year=2007 |pmid=17458185 |doi=}}</ref>
Line 35: Line 35:


==References==
==References==
{{reflist}}
{{reflist|2}}
{{-}}
{{-}}
{{Oral hypoglycemics}}
{{Oral hypoglycemics}}

Latest revision as of 14:28, 6 September 2012

Rivoglitazone
File:Rivoglitazone.svg
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H19N3O4S
Molar mass397.448 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.[1]

It is being developed by Daiichi Sankyo Co.

References

  1. ↑ Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.

Template:Oral hypoglycemics

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Rivoglitazone&oldid=725038"